We’re pleased to share that our scientifically validated probiotic formulations have been officially included in the 2025 edition of the AEProbio Clinical Guide to Probiotic Products – UK Edition.
This independently reviewed clinical reference helps healthcare professionals distinguish between probiotics with proven efficacy and those lacking strong clinical support. Developed by a panel of experts in microbiology, gastroenterology, and nutrition, the guide identifies strain-specific probiotic products backed by human clinical studies. It categorizes formulations by indication (e.g., adult health, pediatric care, women’s health), and assigns each a Recommendation Type based on the strength of evidence:
| Recommendation Type | Criteria |
|---|---|
| Type I | Supported by at least one human clinical trial using the final product/formulation. |
| Type II | Based on clinical evidence from studies using the individual strains included in the product. |
| Type III | Based on expert consensus, in the absence of published human clinical studies. |
The UK guide’s 2025 edition includes four of our formulations, each clinically supported for a specific health indication.
i3.1® — Gut–Brain Axis Modulator for Functional GI Disorders
AEProbio Recommendation: Type I
Indication: Adult Digestive Health (FGIDs, IBS)
i3.1® is a next-generation probiotic targeting the gut–brain axis and visceral hypersensitivity—key drivers in functional gastrointestinal disorders (FGIDs). Its triple mechanism of action—reducing inflammation, correcting dysbiosis, and improving intestinal permeability—has been validated in 7 human clinical trials, including 4 randomized, placebo-controlled studies.
Key findings:
• Reduces abdominal pain, bloating, diarrhea, and constipation.
• Improves emotional well-being and productivity.
• Recognized by multiple international gastroenterology societies.
AB-LIFE® — Cardiometabolic Health Support
AEProbio Recommendation: Type II
Indication: Adult Cardiometabolic Health
AB-LIFE® is a patented blend of Lactiplantibacillus plantarum strains (KABP™ 011, 012, 013) that support cardiometabolic health. Its benefits have been confirmed in five clinical studies, including randomized controlled trials.
Clinically demonstrated effects include:
• Significant reductions in LDL-C, total cholesterol, and triglycerides.
• Improvements in HDL cholesterol and insulin sensitivity.
• Atheroprotective activity, including reductions in ApoB and small dense LDL particles.
Mechanism of action:
• Reduces bile acid recycling through bile salt hydrolase activity.
• Promotes cholesterol excretion and lowers systemic inflammation.
MINDBIOME® — Psychobiotic for Emotional Well-being
AEProbio Recommendation: Type II
Indication: Gut–Brain Axis / Stress & Anxiety
MINDBIOME® contains Lactobacillus plantarum DR7, a proprietary psychobiotic that modulates the microbiota–gut–brain axis. Its clinical efficacy has been established in a 12-week double-blind, placebo-controlled trial.
Clinically supported benefits:
• Reduces perceived stress, anxiety, and depression scores (DASS-42).
• Enhances attention, memory, and cognitive performance.
• Lowers cortisol and inflammatory markers (TNF-α, IFN-γ) while increasing anti-inflammatory IL-10.
Mechanism of action:
• Modulates neurotransmitter synthesis pathways (↑ serotonin, ↓ kynurenine).
• Supports microbial balance, reducing gut dysbiosis associated with stress.
AB-KOLICARE® — Clinically Proven Relief for Infant Colic
AEProbio Recommendation: Type I
Indication: Pediatric Health (Infant Colic, FGIDs)
AB-KOLICARE® is a dual-strain formulation featuring Bifidobacterium longum KABP®042 and Pediococcus pentosaceus KABP®041—both naturally occurring in the infant gut and breast milk.
Its inclusion in the guide is based on placebo-controlled clinical trials showing that the final product:
• Reduces crying and fussing time by 100–150 minutes/day in infants with colic.
• Achieves a 96% responder rate within two weeks of use.
• Demonstrates superior efficacy to L. reuteri DSM17938.
• Increases Bifidobacteria levels and strengthens intestinal barrier function.
Backed by both EFSA (QPS) and FDA (GRAS) approvals, AB-KOLICARE® offers a well-tolerated, natural option for infants from day one.
Inclusion in the AEProbio UK Guide affirms our unwavering commitment to clinical integrity, safety, and innovation. As demand grows for targeted probiotic solutions, healthcare professionals need reliable, independently validated options.
Whether addressing digestive symptoms, cardiovascular risk, mental wellness, or pediatric gut health, our formulations are built on real science, real results, and real impact.